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This population-based study sought to extend knowledge on factors explaining regional dif-
ferences in type 2 diabetes mellitus medication patterns in Germany.
Methods
Individual baseline and follow-up data from four regional population-based German cohort
studies (SHIP [northeast], CARLA [east], HNR [west], KORA [south]) conducted between
1997 and 2010 were pooled and merged with both data on regional deprivation and regional
health care services. To analyze regional differences in any or newer anti-hyperglycemic
medication, medication prevalence ratios (PRs) were estimated using multivariable Poisson
regression models with a robust error variance adjusted gradually for individual and regional
variables.
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Results
The study population consisted of 1,437 people aged 45 to 74 years at baseline, (corre-
sponding to 49 to 83 years at follow-up) with self-reported type 2 diabetes. The prevalence
of receiving any anti-hyperglycemic medication was 16% higher in KORA (PR 1.16 [1.08–
1.25]), 10% higher in CARLA (1.10 [1.01–1.18]), and 7% higher in SHIP (PR 1.07 [1.00–
1.15]) than in HNR. The prevalence of receiving newer anti-hyperglycemic medication was
49% higher in KORA (1.49 [1.09–2.05]), 41% higher in CARLA (1.41 [1.02–1.96]) and 1%
higher in SHIP (1.01 [0.72–1.41]) than in HNR, respectively. After gradual adjustment for
individual variables, regional deprivation and health care services, the effects only changed
slightly.
Conclusions
Neither comprehensive individual factors including socioeconomic status nor regional depri-
vation or indicators of regional health care services were able to sufficiently explain regional
differences in anti-hyperglycemic treatment in Germany. To understand the underlying
causes, further research is needed.
1. Introduction
Diabetes has been proclaimed to be one of the most challenging health problems of the 21st
century [1]. In a Germany-wide survey, the prevalence of known type 2 diabetes mellitus was
estimated to be 7.2% in 2012 [2]. However, regional prevalence estimates showed a southwest-
to-northeast-gradient of type 2 diabetes prevalence with the lowest prevalence in the south
(KORA S4; 5.8%) and the highest estimates in the east (CARLA, 12.0%) [3]. As revealed in fur-
ther analyses, regional differences in type 2 diabetes mellitus prevalence were not solely attrib-
utable to individual characteristics: regional deprivation on municipality and district level as
well as neighborhood unemployment rate turned out to influence type 2 diabetes prevalence
independently [4–7].
Regional differences were also observed in terms of type 2 diabetes mellitus therapy and
outcomes and regional deprivation turned out to be an additional independent factor of grow-
ing importance for health care utilization and outcomes [8]. In a systematic review summariz-
ing the results of 21 studies published between January 2002 and December 2011, Grintsova
et al. pointed out that people with low socioeconomic status (SES) tended to receive worse dia-
betes care (e.g. low frequency of HbA1c measurement) and have poorer intermediate diabetes
outcomes [8]. Living in deprived areas was associated with less frequent achievement of glyce-
mic control targets, a trend towards higher blood pressure and worse lipid profile control.
These results were confirmed by a recently published population based study from North
Karelia Finland [9].
Regional differences in Medicare reimbursement per patient in 2014 were found in the U.S.
with almost two-fold higher expenditures in Florida compared to Alaska [10]. In Germany,
Schipf et al. analyzed the regional prevalence of anti-hyperglycemic medication [3] among par-
ticipants from five population-based studies and found variations between 75.4% (HNR base-
line study) and 86.3% (KORA S4). To explain these differences, another study investigated
associations with participants’ individual characteristics including socioeconomic status [11]
based on data from two of these regional studies (KORA F4, HNR follow-up study). However,
Regional differences in antihyperglycemic medication
PLOS ONE | https://doi.org/10.1371/journal.pone.0191559 January 25, 2018 2 / 16
Research and Health Economics who needs to be
contacted at werner.arend@uni-duesseldorf.de. All
study methods were approved by the Ethics
Committee of the Medical Faculty of the Martin-
Luther-University Halle-Wittenberg and by the
State Data Privacy Commissioner of Saxony-Anhalt
(CARLA), by the Medical Ethics Committee of the
University of Greifswald (SHIP), by the Ethics
Committee of the Bavarian Medical Association
(KORA) and by the institutional local ethical
committees (baseline: Medical faculty University of
Essen; follow-up: Medical faculty University of
Duisburg-Essen) (Heinz Nixdorf Recall (HNR).
Funding: This study was supported by the
Competence Network Diabetes Mellitus (http://
www.kompetenznetz-diabetes-mellitus.net/, FKZ
01GI1110H) and the German Center for Diabetes
Research (https://www.dzd-ev.de/, DZD) both
funded by the German Federal Ministry of
Education and Research (www.bmbf.de, BMBF).
The German Diabetes Center receives institutional
funding by the German Ministry of Health and the
Ministry of Innovation, Sciences and Research of
the Federal State of North Rhine-Westphalia (http://
www.wissenschaft.nrw.de/). The HNR Study was
supported by the Heinz Nixdorf Foundation, Essen,
Germany (http://www.heinz-nixdorf-stiftung.de/
home/), the German Ministry of Education and
Research (www.bmbf.de, BMBF), the Sarstedt AG
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despite considering a wide selection of covariates, among them education, body mass index,
blood pressure, comorbidity, health insurance status, family status, and lifestyle measures,
regional differences in any and newer antihyperglycemic medication (mainly introduced
around the year 2000) could not be explained.
The aim of this study was to extend knowledge on factors explaining regional antihypergly-
cemic medication patterns. Therefore, individual baseline and follow-up data from four
regional population-based studies in Germany were analyzed and complemented by the Ger-
man Index of Multiple Deprivation [4,5] and indicators of regional health care services.
2. Research design and methods
The current study is based on the study methods and contents of Tamayo et al. [11] adding
further study regions, significantly increasing the study population, and extending the study
period.
2.1 Data sources and description of variables
2.1.1 Regional studies and study population. Baseline and follow-up data from four
regional population-based cohort studies carried out in Germany were included (Table 1).
The four studies are comparable in their study design, sampling methods, study population,
and response rates (baseline 56%-69%, follow-up 80%-90%). Study details have been described
previously [12–16]. All studies weremonitored by independent scientific advisory boards. All
participants gave their written consent.
All study methods were approved by the Ethics Committee of the Medical Faculty of the
Martin-Luther-University Halle-Wittenberg and by the State Data Privacy Commissioner of
Saxony-Anhalt (CARLA), by the Medical Ethics Committee of the University of Greifswald
(SHIP), by the Ethics Committee of the Bavarian Medical Association (KORA) and by the
institutional local ethical committees (baseline: Medical faculty University of Essen; follow-up:
Medical faculty University of Duisburg-Essen) (Heinz Nixdorf Recall (HNR). Primary study
data of interest were pooled and frequencies compared.
To increase comparability, participants’ age was limited to 45 to 74 years at baseline, corre-
sponding to 49 to 83 years at follow up. A further inclusion criterion was having type 2 diabe-
tes mellitus at baseline or follow-up examination (defined as self-reported physician’s
diagnosis of diabetes and age at diabetes onset of at least 30 years) resulting in the final study
population of 1,437 participants (Fig 1, Table 1).









(N type 2 diabetes
mellitus)a
The Study of Health in Pomerania (SHIP): Mecklenburg West Pomerania (northeast) 1997–2001 2,277 (251) 2002–2006 1,828 (287)
The Cardiovascular Disease, Living and
Ageing in Halle Study (CARLA)
City of Halle, Saxony-Anhalt (east) 2002–2006 1,417 (174) 2007–2010 1,211 (198)
The Heinz Nixdorf Recall Study (HNR) Cities of Essen, Bochum and Mülheim
(Ruhr area), North Rhine-Westphalia
(west)
2000–2003 4,814 (348) 2006–2008 4,157 (493)
The Cooperative Health Research in the
Region of Augsburg Survey 4 (KORA S4)
City of Augsburg and two surrounding
rural areas, Bavaria (south)
1999–2001 2,524 (146) 2006–2008 1,862 (195)
Total study population 11,032 (919) 9,058 (1,173)
a age group 45 to 74 years at baseline examination (49 to 83 years at follow up examination)
https://doi.org/10.1371/journal.pone.0191559.t001
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2.1.2 Medication. To record medication intake, participants should bring the original
packages of all medications they had used during the seven days preceding the baseline or fol-
low-up examination. According to the corresponding ATC (Anatomical Therapeutic Chemi-
cal Classification System) codes antihyperglycemic and cardiovascular medication were
identified and anti-hyperglycemic medication (A10) were subdivided into all types of insulin
(A10A), and oral anti-hyperglycemic agents (A10B). In accordance with Tamayo et al. and
Waugh et al. [11,17] “newer” anti-hyperglycemic agents were defined as follows:
• Insulin analogues: Lispro (A10AB04, A10AC04) and combinations with Lispro (A10AD04),
Aspart (A10AB05) and combinations (A10AC05, A10AD05), Glulisine (A10AB06), Glargine
(A10AE04), Detemir (A10AE05);
• Newer oral anti-hyperglycemic medications: thiazolidinediones (A10BG: e.g., Rosiglitazone,
Pioglitazone), glinides (A10BX: e.g., Repaglinide, Nateglinide), DPP4-inhibitors (A10BH),
and combinations of thiazolidinediones or glinides with metformin or glimepiride
(A10BD03-A10BD08).
2.1.3 Anthropometry, laboratory, comorbidity. Furthermore, data on body mass index
[kg/m2] (calculated from measured weight and height), systolic and diastolic blood pressure
[mmHg] (mean of the second and third measurement taken by trained personal using vali-
dated automatic devices), and HbA1c [%, mmol/mol] (included despite different assessment
methods to consider the confounding effect in stratified analyses) were included as well as data
Fig 1. Flow-chart study population.
https://doi.org/10.1371/journal.pone.0191559.g001
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on comorbidity (self-reported history of medically confirmed stroke or myocardial infarction),
intake of cardiovascular medication [ATC C]).
2.1.4 Lifestyle. Lifestyle was described using the following components: self-reported
smoking status (divided into “current smokers”, i.e.,1 cigarette/day vs. “never-smokers” or
“ex-smokers” previously smoking1 cigarette/day, but quitting smoking >1 year ago), and
alcohol consumption (“high-risk”: >20/40 g/day in women/men [18,19]; calculated from self-
reported weekly consumption of beer, wine, and liquor [19].
2.1.5 Individual sociodemographic and socioeconomic variables. Family status was
approximated using the dichotomous variable “living with a partner” (yes/no). Educational
level was defined based on the highest achieved schooling degree (“low”: no schooling degree;
“intermediate”: junior high school attendance or secondary school certificate graduation [cor-
responding to at least 8 completed years of schooling]; “high”: high educational graduation
[corresponding to at least 12 completed years of schooling]). Furthermore, the highest
achieved level of vocational qualification was included (“low”: no vocational qualification;
“intermediate”: apprenticeship, completed vocational, technical or master school; “high”: uni-
versity degree; “other”: other vocational qualification). Net household income per month and
household size were used to calculate equivalent income (income/household size0,36) as sug-
gested in the Luxembourg Income Study and used in earlier studies of the DIAB-CORE con-
sortium [5,11].
2.1.6 Regional deprivation. Individual participant data were supplemented by the Ger-
man Index of Multiple Deprivation (GIMD) already used in a number of studies [4,5]. Using
data derived from official statistics (here: mostly from 2006) the index exists on municipality
and district level including seven deprivation domains (income, employment, education,
municipal/district revenue, social capital, environment, security) with higher values represent-
ing more deprived areas. In this study the index was used on district level.
2.1.7 Regional health care services. Indicators of regional health care services on district
level were collected from various sources between 1997 and 2010 (Table 2): the number of hos-
pital beds, physicians, internists per 100,000 inhabitants from official statistics [20,21], the
number of diabetologists/100,000 inhabitants from the German Diabetes Association (DDG),
and the number of diabetes disease management program (DMP) participants/100,000 inhabi-
tants (federal state level) derived from yearly quality reports of the Federal Association of Stat-
utory Health Insurance Physicians (Kassenärztliche Bundesvereinigung) [22].
Table 2. Indicators of health care services included in the analyses.
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https://doi.org/10.1371/journal.pone.0191559.t002
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2.2 Statistical analysis
Individual, regional deprivation and health care services data were merged based on official
district keys. The description was stratified both by examination (baseline, follow up) and by
regional study. Means and standard deviations (SDs) were used for the description of continu-
ous variables. Categorical variables were described by numbers and proportions. Furthermore,
proportions of treatment with anti-hyperglycemic pharmaceuticals were determined.
The association between study region and anti-hyperglycemic treatment was analyzed for
two dependent outcome variables: I. intake of any anti-hyperglycemic medication in the total
sample, II. intake of newer anti-hyperglycemic medication among participants with any anti-
hyperglycemic treatment. Since the prevalence of medication intake was the outcome of inter-
est both baseline and follow-up data were analyzed cross-sectionally. In accordance with Zou
et al.[23] prevalence ratios (PRs) for the intake of any/newer anti-hyperglycemic medication
were estimated by multivariable Poisson regression models with a robust error variance using
log link function. This methodological approach was preferred because of the high prevalence
of all outcomes resulting in overestimations of the true effects when odds ratios from logistic
regression models would be computed instead [24].
To account for the variation between baseline and follow-up examinations, a mixed model
approach was applied for outcome I (any anti-hyperglycemic medication) using “person” as
random effect [25]. Districts and federal states were not considered as random effects because
the number of districts (n = 11) and federal states (n = 4) in the study regions was considerably
low. Since a poisson model was the model of choice, mixed effects poisson models (PROC
GLIMMIX) were calculated. Because of differences in the study periods affecting the availabil-
ity of newer anti-hyperglycemic medication, the association for outcome II was examined
solely among participants of the follow-up examination (N = 894). Hence a standard poisson
model with robust error variance was calculated.
For both outcomes, six basis models were fitted.
• Model 1: crude model
• Model 2: adjusted for individual variables (age, sex, year of examination, diabetes duration)
• Model 3: additionally adjusted for variables of anthropometry and comorbidity
• Model 4: additionally adjusted for lifestyle and individual sociodemographic and socioeco-
nomic variables
• Model 5: additionally adjusted for regional deprivation (GIMD)
• Model 6: additionally adjusted for single indicators of health care services
Because of the high correlation between the regional variables it was not possible to adjust
for all regional health care structure variables in a joint model. Furthermore, the huge number
of regression models did not allow showing PRs for each variable included in the regression
models. For ease of clarity only PRs of the study regions were presented in the resulting tables.




Descriptive data of the study population and anti-hyperglycemic treatment in total as well as
stratified by study and examination are summarized in Tables 3 and 4.
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Table 3. Description of variables.







1 Sex Sex (male, female) categorial 0 0
2 AgeE Age at examination [years] continuous 0 0
3 AgeD Age at diagnosis of diabetes [years] continuous 0 0
4 DD Diabetes duration [years] continuous 0 0
Anthropometry/Comorbidity variables
5 HbA1c
1 HbA1c [%] continuous 10 29
6 HbA1c
2 HbA1c [mmol/mol] continuous 10 29
7 BMI Body mass index [kg/m2] continuous 2 10
8 SBP Systolic blood pressure [mmHg] continuous 3 3
9 DBP Diastolic blood pressure [mmHg] continuous 2 3
10 CVDM Medication of the cardiovascular system (ATC C) continuous 0 0
11 Stroke Previous medically confirmed stroke (yes, no) categorial 4 4
12 MI Previous medically confirmed myocardial infarction categorial 7 4
Lifestyle variables
13 Smoke (No, Ex, Curr) Smoking status (no smoker, former smoker, current smoker) categorial 0 6
14 Alc High-risk alcohol consumption categorial 16 70
Individual sociodemographic/socioeconomic variables
15 Partner Living with a partner (yes, no) categorial 0 3
16 School (Low, Int,
High)
School degree (low, intermediate, high) categorial 0 4
17 Voc (Low, Int, High,
Other)
Vocational qualification (low, intermediate, high, other) categorial 1 2
18 EQHI Equivalent household income [€] continuous 44 100
Ecological variables
19 GIMD Regional deprivation [GIMD-Score] continuous 0 0
Indicators of health care structure
20 Beds Hospital beds/100,000 inhabitants continuous 0 0
21 Phys Physicians/100,000 inhabitants continuous 0 0
22 Int Internists/100,000 inhabitants continuous 0 0
23 Diab Diabetologists/100,000 inhabitants continuous 227 0
24 DMP DMP participants/100,000 inhabitants continuous 919 98
Anti-hyperglycemic treatment (according to ATC-Codes)
25 A10 Any anti-hyperglycemic medication (oral or insulin) (ATC A10) categorial 0 0
26 A10B Total oral anti-hyperglycemic treatment (ATC A10B) categorial 0 0
27 A10BA Metformin (ATC A10BA) categorial 0 0
28 A10BB Sulfonylureas(ATC A10BB) categorial 0 0
29 A10BD Combinations of oral anti-hyperglycemic medication (Metformin Glitazones/
DPP4-inhibitors) (ATC A10BD)
categorial 0 0
30 A10BF α-Glucosidaseinhibitors (Acarbose/Miglitol) (ATC A10BF) categorial 0 0
31 A10BG Thiazolidinediones (Glitazone) (ATC A10BG) categorial 0 0
32 A10BH DPP4-inhibitors (ATC A10BH) categorial 0 0
33 A10BX Glinide (ATC A10BX) categorial 0 0
34 A10A Treatment with any insulin (ATC A10A) categorial 0 0
35 Unknown Unknown medication categorial 0 0
Newer anti-hyperglycemic treatment among participants with any anti-hyperglycemic medication
36 NewMedi All newer medication (insulin analogue and/or oral combinations) categorial 0 0
37 NewOralM Any newer oral medication categorial 0 0
38 NewInsM Any (newer) insulin analogues categorial 0 0
https://doi.org/10.1371/journal.pone.0191559.t003
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Table 4. Characteristics and patterns of anti-hyperglycemic treatment of participants with type 2 diabetes mellitus in the CARLA, KORA, HNR and SHIP studies.























1 Sex, male n (%) 514 (55.9) 96 (55.2) 80 (54.8) 210 (60.3) 128 (51.0) 685 (58.4) 119 (60.1) 110 (56.4) 302 (61.3) 154 (53.7)
2 AgeE (mean, SD) 63.1 (7.2) 63.5 (7.3) 63.3 (6.7) 63.0 (7.2) 62.8 (7.5) 66.9 (7.4) 66.2 (7.3) 68.5 (7.3) 66.8 (7.1) 66.6 (7.9)
3 AgeD (mean, SD) 54.4 (9.3) 54.6 (9.5) 54.6 (9.2) 55.0 (9.5) 53.3 (8.9) 58.1 (10.0) 57.3 (10.0) 59.9 (9.8) 58.9 (9.8) 56.2 (10.0)









a 53 (15) 54 (15) 53 (16) 56 (16) a 51 (11) 51 (11) 51 (13) 52 (14)
7 BMI (mean, SD) 30.9 (5.2) 30.9 (4.9) 32.0 (5.5) 30.4 (5.3) 31.0 (5.1) 31.1 (5.4) 31.3 (5.3) 31.4 (5.5) 30.7 (5.4) 31.3 (5.3)
8 SBP (mean, SD) 145.9(22.3) 150.8(23.0) 144.2(21.6) 141.2(22.2) 150.1 (20.9) 130.0 (21.3) 140.5 (20.5) 132.9 (20.5) 138.7(20.8) 142.4(22.5)
9 DBP (mean, SD) 82.9 (11.4) 85.1 (12.3) 83.1 (12.0) 81.1 (10.7) 84.0 (11.1) 77.7 (10.9) 78.5 (10.3) 74.0 (10.4) 77.5 (10.6) 79.8(11.5)
10 CVDM n (%) 701(76.3) 148(85.1) 103(70.6) 250(71.8) 200(79.7) 1011(86.2) 181(91.4) 163(83.6) 412(83.6) 255(88.9)
11 Stroke n (%) 57(6.2) 13(7.5) 5(3.4) 23(6.7) 16(6.4) 85(7.3) 15(7.7) 12(6.2) 37(7.5) 21(7.4)
12 MI n (%) 94(10.3) 12(7.0) 15(10.3) 37(10.7) 30(12.2) 123(10.5) 18(9.2) 21(10.8) 48(9.7) 36(12.6)
Lifestyle variables
13 Smoke
No 439 (47.8) 82(47.1) 65(44.5) 151(43.4) 141(56.2) 464(39.8) 75(38.3) 75(38.5) 195(39.6) 119(41.9)
Ex 339 (36.9) 64(36.8) 63(43.2) 133(38.2) 79(31.5) 547(46.9) 86(43.9) 98(50.3) 227(46.1) 136(47.9)
Curr 141 (15.3) 28(16.1) 18(12.3) 64(18.4) 31(12.4) 156(13.4) 35(17.9) 22(11.3) 70(14.2) 29(10.2)
14 Alc n (%) 58(6.4) 7(4.0) 21(14.5) 18(5.4) 12(4.8) 75(6.8) 11(5.6) 23(11.8) 30(6.3) 11(4.7)
Individual sociodemographic/socioeconomic variables
15 Partner n (%) 702(76.4) 126(72.4) 111(76.0) 279(80.2) 186(74.1) 905(77.4) 145(74.0) 147(75.4) 401(81.5) 212(73.9)
16 School n (%)
Low 40(4.4) 12(6.9) 6(4.1) 10(2.9) 12(4.8) 37(3.2) 11(5.6) 5(2.6) 11(2.2) 10(3.5)
Int 759(82.6) 129(74.1) 126(86.3) 285(81.9) 219(87.3) 959(82.0) 144(72.7) 164(84.1) 400(81.6) 251(87.8)
High 120(13.1) 33(19.0) 14(9.6) 53(15.2) 20(8.0) 173(14.8) 43(21.7) 26(13.3) 79(16.1) 25(8.7)
17 Voc n (%)
Low 180(19.6) 13(7.5) 45(30.8) 59(17.0) 63(25.1) 170(14.5) 9(4.6) 33(16.9) 68(13.8) 60(21.0)
Int 620(67.5) 140(80.5) 92(63.0) 239(68.9) 149(59.4) 841(71.8) 163(82.3) 140(71.8) 355(72.2) 183(64.0)
High 104(11.3) 11(6.3) 9(6.2) 49(14.1) 35(13.9) 146(12.5) 14(7.1) 22(11.3) 69(14.0) 41(14.3)
Other 14(1.5) 10(5.8) 0(0.0) 0(0.0) 4(1.6) 14(1.2) 12(6.1) 0(0.0) 0(0.0) 2(0.7)





















19 GIMD(mean,SD) 32.6 (12.0) 35.9 (0.0) 18.5 (12.8) 26.8 (4.1) 46.7 (6.2) 31.6 (12.1) 35.9 (0.0) 18.0 (12.7) 26.3 (4.1) 47.0 (6.2)
Indicators of health care structure










21 Phys (mean, SD) 171 (42.6) 223.3 (2.0) 174.2 (53.2) 147.7 (6.8) 165.1 (47.4) 179.2 (47.3) 235.3 (4.1) 189.1 (59.7) 154.1 (6.4) 176.8 (57.6)
22 Int (mean, SD) 25.0 (6.4) 30.4 (0.7) 22.2 (8.8) 27.8 (3.2) 18.9 (4.1) 27.5 (7.0) 35.0 (1.5) 24.8 (9.6) 28.3 (3.3) 22.8 (7.2)
23 Diab (mean, SD) 4.3 (2.2) 3.6 (0.6) 2.0 (1.4) 5.2 (1.8) 6.5 (3.9) 5.7 (3.2) 4.3 (0.0) 2.8 (1.8) 7.4 (2.2) 5.9 (4.5)










Anti-hyperglycemic treatment (according to ATC-Codes)c
25 A10 n (%) 685(74.5) 137(78.7) 121(82.9) 242(69.5) 185(73.7) 894(76.2) 153(77.3) 161(82.6) 356(72.2) 224(78.1)
(Continued)
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3.2. Determinants of any anti-hyperglycemic medication in the total study
population
Table 5 summarizes pairwise PRs for any anti-hyperglycemic medication. According to the
results of the crude model 1, treatment patterns varied by study region. KORA participants
were more likely to receive any anti-hyperglycemic medication than participants from all
other studies, while least prescriptions were found in HNR. These differences were indepen-
dent from all individual variables (models 2–4). The regional differences persisted after adjust-
ment for regional deprivation (model 5). Further adjustment for single indicators of health
care structure (model 6) resulted in mostly minor variations of PRs. The statistically significant
difference in the medication prevalence between KORA vs. HNR reported in models 1 to 5
remained in the same order of magnitude with PRs ranging between 1.12 after adjustment for
DMP participants/100,000 inhabitants and 1.15 after adjustment for diabetologists/100,000
inhabitants.
Regarding the effect of other independent variables, the prevalence of receiving anti-hyper-
glycemic medication increased significantly with increasing diabetes duration, HbA1c and
intake of cardiovascular medication in all regression models (all p<0.001; data not shown).
Furthermore, increasing diastolic blood pressure was predominantly associated with decreased
prevalence of anti-hyperglycemic medication.
3.3. Determinants of newer anti-hyperglycemic medication among people
with any anti-hyperglycemic treatment
As shown in Table 6, regional differences in the prevalence of receiving newer anti-hyperglyce-
mic medication were more pronounced than regarding any anti-hyperglycemic medication.
Table 4. (Continued)





















26 A10B n (%) 544(59.2) 112(64.4) 100(68.5) 192(55.2) 140(55.8) 746(63.6) 128(64.7) 139(71.3) 302(61.3) 177(61.7)
27 A10BA n (%) 322(35.0) 63(36.2) 55(37.7) 131(37.6) 73(29.1) 538(45.9) 83(41.9) 95(48.7) 234(47.5) 126(43.9)
28 A10BB n (%) 306(33.3) 58(33.3) 62(42.5) 95(27.3) 91(36.3) 305(26.0) 54(27.3) 59(30.3) 114(23.1) 78(27.2)
29 A10BD n (%) 0(0.0) 0(0.0) 0(0.0) 0(0.0) 0(0.0) 23(2.0) 5(2.5) 7(3.6) 8(1.6) 3(1.1)
30 A10BF n (%) 52(5.7) 11(6.3) 14(9.6) 18(5.2) 9(3.6) 19(1.6) 8(4.0) 3(1.5) 4(0.8) 4(1.4)
31 A10BG n (%) 14(1.5) 7(4.0) 0(0.0) 7(2.0) 0(0.0) 34(2.9) 3(1.5) 11(5.6) 11(2.2) 9(3.1)
32 A10BH n (%) 0(0.0) 0(0.0) 0(0.0) 0(0.0) 0(0.0) 4(0.3) 1(0.5) 1(0.5) 2(0.4) 0(0.0)
33 A10BX n (%) 27(2.9) 9(5.2) 1(0.7) 15(4.3) 2(0.8) 44(3.8) 8(4.0) 6(3.1) 22(4.5) 8(2.8)
34 A10A) n (%) 233(25.4) 55(31.6) 39(26.7) 68(19.5) 71(28.3) 279(23.8) 54(27.3) 47(24.1) 90(18.3) 88(30.7)
35 Unknown n (%) 3(0.3) 0(0.0) 0(0.0) 3(0.9) 0(0.0) 4(0.3) 0(0.0) 0(0.0) 4(0.8) 0(0.0)
Newer anti-hyperglycemic treatment among participants with any anti-hyperglycemic medication (nbaseline = 685, nfollow up = 894)
c,d
36 NewMedi n (%) 100(14.6) 34(24.8) 6(5.0) 48(19.8) 12(6.5) 207(23.2) 43(28.1) 48(29.8) 71(19.9) 45(20.1)
37 NewOralM n (%) 40(5.8) 16(11.7) 1(0.8) 21(8.7) 2(1.1) 101(11.3) 16(10.5) 24(14.9) 41(11.5) 20(8.9)
38 NewInsM n (%) 64(9.3) 21(15.3) 5(4.1) 28(11.6) 10(5.4) 119(13.3) 29(19.0) 29(18.0) 34(9.6) 27(12.1)
Data are described as proportion or mean (SD)
a Not summable because of study differences in blood samples, measurement methods and standard operating procedures.
b Because disease management programs (DMPs) for diabetes have been implemented only in 2002, this analysis was restricted to follow up observations.
c Multiple entries possible
d Percentages based on individuals with any anti-hyperglycemic treatment (ATC: A10).
https://doi.org/10.1371/journal.pone.0191559.t004
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According to the crude model 1, regional differences varied between 1% and 49% with signifi-
cantly higher proportions in KORA and CARLA compared with HNR. After adjustment for
individual basis variables (model 2), the difference between KORA vs. HNR increased while
the difference between CARLA vs. HNR decreased and was no longer statistically significant.
Adjustments for further individual variables (models 3–4) changed PRs only marginally. Addi-
tional adjustment for regional deprivation (model 5) increased regional differences in the
prevalence of receiving newer anti-hyperglycemic medication between KORA vs. HNR, while
the difference between CARLA vs. HNR decreased (not statistically significant). After further
inclusion of single indicators of health care structure, significant differences in the regional
prevalence of newer anti-hyperglycemic medication between KORA and HNR mainly per-
sisted while the direction of the change in PRs for CARLA or SHIP vs. HNR was inconsistent
and depended on the included indicator of health care structures.
Regarding the effect of other independent variables, the prevalence of receiving newer anti-
hyperglycemic medication was higher with increasing diabetes duration and HbA1c in most
regression models, but lower with increasing age (data not shown).
Table 5. Multivariable prevalence ratios of anti-hyperglycemic medication.
KORA vs. HNR CARLA vs. HNR SHIP vs. HNR
Model 1 1.16 (1.08–1.25) 1.10 (1.01–1.18) 1.07 (1.00–1.15)
Models 2–4 adjusted for individual variables
Model 2 1.16 (1.08–1.24) 1.08 (1.00–1.17) 1.06 (0.98–1.14)
Model 3 1.16 (1.08–1.24) 1.08 (1.00–1.16) 1.05 (0.98–1.13)
Model 4 1.14 (1.06–1.23) 1.07 (0.99–1.16) 1.03 (0.94–1.12)
Model 5 adjusted for individual variables (model 4) + regional deprivation (GIMD)
GIMD 1.14 (1.06–1.23) 1.07 (0.98–1.16) 1.02 (0.91–1.15)
Model 6 adjusted for individual variables + regional deprivation (GIMD; model 5) + single indicators of health
care structure
Hospital beds/100,000 inhabitants 1.14 (1.06–1.23) 1.08 (0.99–1.18) 1.04 (0.93–1.17)
Physicians/100,000 inhabitants 1.14 (1.5–1.25) 1.08 (0.98–1.18) 1.04 (0.93–1.17)
Internists/100,000 inhabitants 1.14 (1.06–1.23) 1.08 (0.99–1.18) 1.01 (0.87–1.16)
Diabetologists/100,000 inhabitants 1.15 (1.06–1.25) 1.10 (1.00–1.21) 1.08 (0.96–1.22)
DMP participants/100,000 inhabitantsa 1.12 (1.01–1.24) 1.14 (0.93–1.39) 1.00 (0.82–1.22)
Prevalence ratios and 95% CIs derived from mixed effects Poisson models with robust error variance
 p<0.05
a Because disease management programs (DMPs) for diabetes have been implemented only in 2002, this analysis was
restricted to follow up observations.
Model 1 crude model (N = 1,437, 2,092 observations)
Model 2: adjusted for age, sex, year of examination, and diabetes duration (N = 1,437, 2,092 observations)
Model 3: Model 2 + additional adjustment for HbA1C, body mass index, systolic blood pressure, diastolic blood
pressure, medication of the cardiovascular system, self-reported medically confirmed myocardial infarction, and self-
reported medically confirmedstroke (N = 1,408, 2,027 observations)
Model 4: Model 3 + additional adjustment for smoking status, alcohol consumption, living with a partner, school
degree, vocational qualification, and equivalent household income (N = 1,322, 1,825 observations)
Models 5: Model 4 + additional adjustment for regional deprivation (GIMD; N = 1,322, 1,825 observations),
Model 6: Model 5 + additional single adjustment for hospital beds/100,000 inhabitants (N = 1,322, 1,825
observations), physicians per 100,000 inhabitants (N = 1,322, 1,825 observations), internists per 100,000 inhabitants
(N = 1,322, 1,825 observations), diabetologists/100,000 inhabitants (N = 1,212, 1,619 observations), or DMP
participants/100,000 inhabitants (N = 923, 923 observations)
https://doi.org/10.1371/journal.pone.0191559.t005
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4. Discussion
4.1 Key results
Analyses of medication data from four longitudinal, population-based German studies partly
showed considerable regional differences in anti-hyperglycemic medication with differences
in newer medication prevalence of up to 49%. Regarding any anti-hyperglycemic medication,
neither adjustment for individual variables, regional deprivation nor indicators of health care
services could completely explain regional differences. Compared with any anti-hyperglycemic
medication, regional differences in the prevalence of receiving any newer anti-hyperglycemic
medication were more pronounced. The prevalence of receiving anti-hyperglycemic and
newer medication was thereby highest in the south and lowest in the west. After adjustment
for individual variables statistically significant regional differences persisted only for KORA
(south) vs. HNR (west). Despite extensive adjustment regional differences in the prevalence of
any as well as newer anti-hyperglycemic medication mainly remained indicating associations
with further influencing factors not captured in the present analyses.
Table 6. Multivariable prevalence ratios of new antihyperglycemic medication among participants with any anti-
hyperglycemic medication.
KORA vs. HNR CARLA vs. HNR SHIP vs. HNR
Model 1 1.49 (1.09–2.05) 1.41 (1.02–1.96) 1.01 (0.72–1.41)
Models 2–4 adjusted for individual variables
Model 2 1.57 (1.16–2.14) 1.29 (0.91–1.82) 1.04 (0.57–1.90)
Model 3 1.61 (1.18–2.19) 1.30 (0.91–1.86) 1.18 (0.64–2.18)
Model 4 1.54 (1.12–2.13) 1.20 (0.82–1.76) 1.30 (0.61–2.80)
Model 5 adjusted for individual variables (model 4) + regional deprivation (GIMD)
GIMD Score 1.67 (1.20–2.32) 1.05 (0.70–1.57) 0.99 (0.43–2.31)
Model 6 adjusted for individual variables + regional deprivation (GIMD; model 5) + single indicators of health
care structure
Hospital beds/100,000 inhabitants 1.66 (1.20–2.31) 1.10 (0.72–1.67) 1.08 (0.45–2.58)
Physicians/100,000 inhabitants 1.33 (0.87–2.02) 0.88 (0.55–1.39) 1.18 (0.51–2.75)
Internists/100,000 inhabitants 1.56 (1.13–2.16) 0.99 (0.65–1.49) 1.76 (0.70–4.41)
Diabetologists/100,000 inhabitants 1.68 (1.18–2.40) 1.06 (0.67–1.67) 1.00 (0.43–2.30)
DMP participants/100,000 inhabitantsa 2.03 (1.35–3.05) 0.51 (0.20–1.30) 1.97 (0.75–5.15)
Prevalence ratios and 95% CIs derived from Poisson models with robust error variance
 p<0.05
a Because disease management programs (DMPs) for diabetes have been implemented only in 2002, this analysis was
restricted to follow up observations.
Model 1: crude model (N = 894)
Model 2: adjusted for age, sex, year of examination and diabetes duration (N = 894)
Model 3: Model 2 + additional adjustment for HbA1C, body mass index, systolic blood pressure, diastolic blood
pressure, medication of the cardiovascular system, self-reported medically confirmedmyocardial infarction, and self-
reported medically confirmedstroke (N = 863)
Model 4: Model 3 + additional adjustment for smoking, alcohol consumption, living with a partner, school degree,
vocational qualification, equivalent household income (N = 750)
Models 5: Model 4 + additional adjustment for regional deprivation (N = 750)
Model 6: Model 5 + additional single adjustment for hospital beds/100,000 inhabitants (N = 750), physicians per
100,000 inhabitants (N = 750), internists per 100,000 inhabitants (N = 750), diabetologists/100,000 inhabitants
(N = 750), or DMP participants/100,000 inhabitants (N = 696)
https://doi.org/10.1371/journal.pone.0191559.t006
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4.2 Comparison with other studies
Although the interest in health care differences and the underlying causes is high and further
growing, corresponding literature remains scarce. Especially individual and regional associa-
tions have rarely been analyzed simultaneously. Compared with previous results by Tamayo
et al. adjusted for individual variables [11], regional differences in any anti-hyperglycemic
medication between KORA (south) and HNR (west) were confirmed, and further differences
between CARLA (east) vs. HNR (west) appeared. However, there was no consistent difference
between the studies from western (KORA, HNR) and the studies from eastern Germany
(SHIP, CARLA) in contrast to some other previously reported health outcomes [26]. The cur-
rent findings support the results by Tamayo et al. suggesting that individual variables explain
regional differences inadequately. Although regional deprivation could partly explain these
differences in type 2 diabetes mellitus prevalence [4–6], regional deprivation seems not to be
of significant importance in the explanation of differences in antihyperglycemic medication in
this study either.
Comparisons with studies from other countries are limited because of differences in
regional structures and health care systems (especially regarding the reimbursement of anti-
hyperglycemic medication) [27]. The association between regional deprivation and worse
diabetes outcomes reported in the review by Grintsova et al. [8], was not found for anti-hyper-
glycemic medication in this study. However, it is unknown if a higher proportion of medica-
tion use implicate a worse or better quality of treatment or even a mixture of both masking
potential apparent differences in diabetes care as a consequence. In Belgium, Wens et al. dem-
onstrated regional differences in the first utilization of anti-hyperglycemic medication (sul-
phonylureas vs. biguanides) independent of body mass index, HbA1c, serum cholesterol and
triglycerides [28]. In Germany, the utilization of the biguanide metformin is still recom-
mended as first choice medication in the national diabetes guidelines {Bundesärztekammer
(BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftli-
chen Medizinischen Fachgesellschaften (AWMF), Arzneimittelkommission der deutschen
Ärzteschaft (AkdÄ), Deutsche Diabetes Gesellschaft (DDG), Deutsche Gesellschaft für Allge-
meinmedizin und Familienmedizin (DEGAM), Deutsche Gesellschaft für Innere Medizin
(DGIM), Verband der Diabetesberatungs- und Schulungsberufe Deutschland [29]. Corre-
spondingly, metformin utilization at follow-up was consistently higher in all current studies
than utilization of sulfonylureas. Moreover, analyses of the variability of prescribing for diabe-
tes and secondary preventative therapies revealed large differences between eight Irish health
board regions not explainable by differences in the distribution of age and gender [30]. How-
ever, socioeconomic differences and differences in health care services between the regions
were not considered in the respective study.
4.3 Implications
Summarizing the current results neither individual variables including individual socio eco-
nomic status nor regional variables describing regional deprivation and health care services
were able to sufficiently explain regional differences in any and newer anti-hyperglycemic
treatment. To understand the underlying causes, future studies may also consider the influence
of individual health behavior (e.g., dietary behavior, diabetes knowledge, health literacy, atti-
tudes, wishes, and compliance regarding diabetes therapy), physicians0 attitudes (e.g., regard-
ing continual medical education and prescriptions), physician-patient interactions and
reimbursement, the quality and utilization of regional health care services, and the prevalence
of chronic stress and mental health problems. Further, possible differences in the detection of
diabetes have to be taken into account. In addition, analyses of regional differences based on
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small-area data, e.g. at the municipal level, might be more informative. Another point of inter-
est is the association between regional differences in anti-hyperglycemic treatment and long-
term diabetes outcomes.
Interestingly, regional differences as reflected by PRs seemed to be more pronounced
regarding the prevalence of newer anti-hyperglycemic medication compared with any anti-
hyperglycemic medication (in line with the study by Tamayo et al. [11]). The underlying
causes are not known to date. Maybe, differences in the budgets of the treating physicians
depending on the regionally organized Associations of Statutory Health Insurance Physicians
(Kassenärztliche Vereinigungen) and differences in health insurance membership of the
treated patients (selective contracts, statutory vs. private health insurance) are of importance
in this context.
4.4 Strengths and limitations
The strengths of our study are the utilization of data from four German regional population-
based studies with high comparability regarding sampling procedure, study design, and assess-
ment tools. For the first time in Germany and elsewhere, individual socio economic status, life-
style factors, regional deprivation, and differences in health care services were considered
together trying to explain differences in antihyperglycemic medication in general and stratified
by type of medication in a large sample of participants.
However, this study is limited by differences in the periods of data collection between the
studies. Although response rates were similar (baseline 56%-69%, follow-up 80%-90%), differ-
ences in nonresponse may have biased the regional analyses. The use of districts as regional
reference may have led to distortion of the results because of heterogeneous geographical sizes
and numbers of inhabitants. Another limitation is that individual data on health insurance sta-
tus (statutorily or privately insured) were not available for all studies. Furthermore, the results
of model 6 should be interpreted with caution in the context of an increased uncertainty of
estimates and standard errors due to high collinearity of regional variables with study region.
To ensure a uniform procedure it was decided to limit the analysis of new anti-hyperglycemic
medication to follow-up data, although the time of the baseline examination of some studies
overlapped with the study period at follow-up of others. In addition, PRs regarding new anti-
hyperglycemic medication were often not statistically significant despite partly considerably
regional differences due to low statistical power.
In conclusion, for the first time, regional differences in any and newer anti-hyperglycemic
treatment have been demonstrated based on data from four regional population-based studies
in Germany. Because neither comprehensive individual variables nor regional deprivation and
health care services were able to sufficiently explain regional differences, further research is
needed to understand the underlying causes, assess implications for type 2 diabetes mellitus
outcomes, and plan interventions for deprived target groups.
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